JBIO · Forms 3, 4, 5
Insider trades at Jade Biosciences, Inc.
No open-market insider buys or sells at Jade Biosciences, Inc. in the last 90 days; 10 filings reported awards, option exercises, tax withholding or new insiders.
Every Form 3, 4 and 5 filed for Jade Biosciences, Inc. (JBIO) with the SEC, newest first: who traded, their role, buy or sell, shares, price and value.
Most recent insider filings
No Form 3, 4 or 5 filings for Jade Biosciences, Inc. in the last 90 days. The latest ones on EDGAR:
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Mark Eisner | Director | Options or other derivatives | Form 4 | ||||
| Mark Eisner | Director | Became an insider (Form 3) | Form 3 | ||||
| Christopher W. Cain | Director | Options or other derivatives | Form 4 | ||||
| Eric Dobmeier | Director | Options or other derivatives | Form 4 | ||||
| Lawrence Otto Klein | Director | Options or other derivatives | Form 4 | ||||
| Erin Lavelle | Director | Options or other derivatives | Form 4 | ||||
| Fairmount Funds Management LLC | Director | Options or other derivatives | Form 4 | ||||
| Bradford D. Dahms | Chief Financial Officer | Award | 37,813 | Form 4 | |||
| Elizabeth Balta | Officer | Award | 28,125 | Form 4 | |||
| Tom Frohlich | Chief Executive Officer | Award | 78,750 | Form 4 |
Buy and Sell are open-market purchases and sales (transaction codes P and S), the trades investors watch. Awards, option exercises, tax withholding and gifts are reported too but are not market trades.